• PD 0332991 Workflow for CDK4/6 Assays

  2026-08-19

  Build more informative CDK4/6 experiments with PD 0332991 by pairing G1-arrest and Rb readouts with proliferation, migration, and pathway assays. This workflow also translates recent pancreatic cancer findings into practical combination-testing and troubleshooting strategies.

• SIRT1/2 Inhibitor IV: CNS and Tumor Workflows

  2026-08-19

  SIRT1/2 Inhibitor IV (cambinol) enables controlled interrogation of SIRT1/2-dependent deacetylation in lactate-responsive astrocytes, hypoxia studies, and cancer models. This practical guide connects dose-finding, Ran lactylation and STAT3 localization assays with p53 acetylation, tubulin acetylation, apoptosis, and xenograft workflows.

• (S)-Mephenytoin in CYP2C19 Organoids

  2026-08-18

  Use (S)-Mephenytoin as a functional CYP2C19 substrate probe in hiPSC-derived intestinal organoids, where epithelial maturation, transport, and oxidative metabolism can be assessed together. This workflow connects a defined enzyme substrate with a more human-relevant pharmacokinetic model while providing practical controls for solubility, matrix effects, and variable CYP activity.

• Mouse Tissue Lysis Kit (K1038) Workflow

  2026-08-18

  The Mouse Tissue Lysis Kit (K1038) prepares mouse tissue lysates for direct PCR-based genotyping without a separate DNA extraction or purification step. It is intended for research workflows such as genotyping assays and DNA analysis, not diagnostic, clinical, or medical use.

• Sulfachloropyridazine Research Workflows

  2026-08-17

  Sulfachloropyridazine connects DHPS biochemistry with antimicrobial susceptibility testing, microbial ecology studies, and infection-model readouts. This workflow-focused guide shows how to control solubility, build interpretable dose responses, and pair microbiome data with metabolomics without confusing association with mechanism.

• a-MSH, Amide: Pigmentation Research Guide

  2026-08-17

  a-MSH, amide is a synthetic alpha-melanocyte-stimulating hormone amide used to model MC1R-linked pigmentation and melanogenesis pathways. Its defined sequence, molecular weight, solubility profile, and storage requirements support controlled pigmentation regulation research and receptor pharmacology workflows.

• Lambda Protein Phosphatase (RNase-free): Assay Guide

  2026-08-16

  Learn how Lambda Protein Phosphatase (RNase-free), SKU K1102, can strengthen phosphorylation controls in cell viability, proliferation, cytotoxicity, and circadian biology workflows. This scenario-based guide covers inhibitor compatibility, reaction setup, antibody validation, data interpretation, and practical product selection.

• 15-PGDH Inhibition Supports Muscle Repair in Weight Loss

  2026-08-15

  The reference study identifies 15-PGDH inhibition as a strategy for improving muscle regeneration and force recovery during semaglutide-associated weight loss in obese mice. Its key contribution is showing that a 15-PGDH inhibitor can enhance muscle stem cell activity and regenerated myofiber growth without diminishing semaglutide-mediated weight reduction.

• Lyso-Tracker Red for Nanoparticle Trafficking

  2026-08-14

  Discover how Lyso-Tracker Red supports lysosome labeling in live cells and helps distinguish nanoparticle uptake, acidic compartment routing, and lysosomal escape. This article translates findings from a laminarin vaccine-nanoparticle study into practical assay decisions.

• TRPM3 Regulation by Neurosteroids and Primidone

  2026-08-14

  The reference study defines how pregnenolone sulfate, CIM 0216, and primidone interact with the TRPM3 channel by combining cryo-EM structures with electrophysiology, molecular dynamics, and biochemical analyses. Its findings connect ligand recognition to TRPM3 gating and provide a structural framework for interpreting gain-of-function disease mutations and developing TRPM3-directed therapies.

• ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors

  2026-08-13

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. It also reports enhanced toxicity when these inhibitors are combined with Temozolomide, supporting further investigation of ATRX status in glioma treatment-response studies.

• SW033291: A 15-PGDH Inhibitor Workflow

  2026-08-13

  SW033291 provides a precise way to connect 15-PGDH inhibition with prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue regeneration research. This workflow translates recent muscle-repair findings into practical enzyme, cell, and translational assay designs while emphasizing controls and troubleshooting.

• Tacrine Hydrochloride Hydrate: Assay Logic

  2026-08-12

  Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, is examined here as a reference compound for mechanism-resolved Alzheimer’s disease research. This article focuses on exposure control, assay interpretation, and metabolism-aware experimental design rather than repeating a conventional drug-development overview.

• Targeted NAC Nanoparticles Suppress OA Ferroptosis

  2026-08-12

  The reference study develops chondroitin sulfate-modified PLGA nanoparticles that prolong intra-articular NAC exposure and target chondrocytes in osteoarthritis. Its results connect glutathione maintenance and GPX4-dependent ferroptosis inhibition with reduced cartilage damage, providing a mechanistic framework for localized redox therapy.

• Talabostat mesylate: DPP4/FAP Research Workflows

  2026-08-11

  Talabostat mesylate, also called PT-100 or Val-boroPro, supports parallel investigation of DPP4/FAP biology, tumor microenvironment modulation, and CARD8-dependent pyroptosis. This workflow-oriented guide shows how to separate protease inhibition from T-cell fate effects, improve solution handling, and build interpretable cancer and immunology assays.

15801 records 1/1054 page Next 12345 下5页 Last page